Familial clustering of lone atrial fibrillation in patients with saddleback-type ST-segment elevation in right precordial leads

Size: px
Start display at page:

Download "Familial clustering of lone atrial fibrillation in patients with saddleback-type ST-segment elevation in right precordial leads"

Transcription

1 European Heart Journal (2007) 28, doi: /eurheartj/ehl474 Clinical research Arrhythmia/electrophysiology Familial clustering of lone atrial fibrillation in patients with saddleback-type ST-segment elevation in right precordial leads M. Juhani Junttila 1 *, M.J. Pekka Raatikainen 1, Juha S. Perkiömäki 1, Kui Hong 2, Ramon Brugada 3, and Heikki V. Huikuri 1 1 Department of Internal Medicine, Division of Cardiology, University of Oulu, PO Box 5000, Oulu 90014, Finland; 2 Baylor College of Medicine, Houston, TX, USA; and 3 Montreal Heart Institute, Montreal, Canada Received 7 September 2006; revised 28 November 2006; accepted 21 December 2006; online publish-ahead-of-print 22 January 2007 KEYWORDS Atrial fibrillation; Inherited arrhythmias; Electrocardiogram Introduction Lone atrial fibrillation (AF) is defined as an arrhythmic disorder in patients with no clinical or echocardiographic evidence of cardiopulmonary disease or any other secondary cause of AF. The patients are typically under 60 years of age and have a favourable prognosis with respect to thrombo-embolism and mortality. Several population-based studies have recently noted a familial aggregation of AF and a high risk of lone AF in individuals with parental AF. 1 4 Although the knowledge of the mechanisms of AF has increased markedly during recent years, the molecular and genetic backgrounds of the initiation and perpetuation of AF are largely unknown. 5 In particular, more data on the potential role of genetic factors in the pathogenesis of AF are needed. Elevation of the ST-segment in the right precordial ECG leads V 1 3 has been previously linked to the Brugada syndrome. 6 Brugada syndrome is a hereditary cardiac ion channelopathy, which predisposes the patients not only to ventricular tachyarrhythmias (VT) and sudden cardiac death (SCD), but also to supraventricular arrhythmias * Corresponding author. Tel: þ ; fax: þ address: mattiju@mail.student.oulu.fi Aims We recently identified a large family with a high prevalence of lone atrial fibrillation (AF) and saddleback-type ST-segment elevation in leads V 1 3, without a history of ventricular arrhythmias or syncope. On the basis of this finding, we studied whether there is a relationship between saddleback ST-elevation and lone AF. Methods and results We examined 168 (mean age 50+8 years, 130 males) lone AF patients and 541 (mean age 50+6 years, 274 males) healthy subjects. The prevalence of saddleback ST-elevation was higher in the lone AF group than the control group (10 vs. 0.4%, P, 0.001). None had a coved-type ST-elevation in baseline ECG or during drug challenge with ajmaline or flecainide (n ¼ 13), a family history of sudden cardiac death, ventricular tachyarrhythmias, syncope, or any other features diagnostic to the Brugada syndrome. Familial clustering of lone AF (i.e. AF in.30% of first-degree relatives) was more common among the subjects with saddleback ST-elevation (24 vs. 7%, P ¼ 0.03). Conclusion Saddleback-type ST-segment elevation is a relatively common finding among patients with lone AF. The familial clustering of the disorder indicates that genetic factors may be involved in the pathogenesis of the ECG abnormality and lone AF in these patients. including AF. 7 9 However, saddleback-type ST-segment elevation (type 2 and 3 Brugada ECG abnormalities) has also been observed in healthy subjects without any VT or family history of SCD These ECG abnormalities seem to be benign and have been considered as normal variants Given the association between the Brugada syndrome and AF and the anecdotal data 10 from our laboratory that saddleback-type ST-segment elevation in right precordial leads V 1 3 may predispose to AF, we decided to investigate whether there is a relationship between saddleback-type ST-segment elevation and lone AF. Our hypothesis was that saddleback-type ST-segment elevation would predispose patients to familial AF but not to syncope, VT, and SCD. Methods Lone AF population The lone AF population was selected among 220 consecutive patients admitted into Oulu University Hospital for treatment of acute AF or catheter ablation of AF during the years 2002 and A total of 168 patients of them consented to the study. Their mean age was 50+8 years (range years), and 130 (77%) of them were male. All subjects with a history of any cardiovascular, pulmonary (e.g. asthma), or metabolic & The European Society of Cardiology All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org

2 464 M.J. Junttila et al. (e.g. hyperthyroidism and diabetes) diseases or with hypertension were excluded. Other exclusion criteria were electrical or medical cardioversion within 30 days before the examination, history of thoracic surgery or radio frequency catheter ablation, permanent pacemaker, and any of the following echocardiographic findings: depressed left ventricular systolic function (ejection fraction,50%), abnormal wall motion of the left ventricle, septal hypertrophy (.15 mm), left atrial (LA) size.50 mm, and significant valve abnormality. The study protocol was approved by the local institutional Ethics Committee and written informed consent was obtained from all study subjects. Control population The control population was selected among the subjects who had initially participated in the Opera study. 17 In the Opera study, 300 women and 300 men between 40 and 60 years of age were randomly selected from the National Social Insurance Register. The subjects underwent a thorough physical examination, 12-lead ECG transthoracic echocardiography, and extensive laboratory tests in Oulu University Hospital during the years 1991 and 1992 to ensure that they had no cardiovascular, pulmonary, or metabolic disorders or documented arrhythmias. 17 All subjects with antihypertensive or cardiac medication were excluded and 541 consented to the current study. The mean age of the control subjects was 50+6 years (range 46 60), and 274 (51%) of them were male. Analysis of ECGs Two independent investigators reviewed all the 12-lead ECGs (paper speed 50 mm/s and 1 mv/10 mm standard gain). The ECG criteria devised by the Study Group of the Molecular Basis of Arrhythmias of the European Society of Cardiology were used to identify the subjects with saddleback-type ST-segment elevation concomitant to type 2 and 3 Brugada ECG patterns. 18 The diagnosis saddleback-type ST-segment elevation was made when both investigators agreed on the classification of the ECG abnormality. The authors of the Brugada syndrome consensus report recommended the use of diagnostic drug challenge with a class IC antiarrhythmic agent to unmask the coved-type ST-segment elevation among the subjects with type 2 or 3 ECG changes in the baseline ECG. 16 Therefore, a diagnostic drug challenge with flecainide (150 mg or 2 mg/kg over 10 min) or ajmaline (50 mg or 1 mg/kg over 5 min) was offered to all the subjects with a saddleback-type ST-segment elevation and a history of AF episodes. Thirteen subjects (76%) consented to the test. Clinical characteristics and family history of patients with lone AF The family history of AF, syncope, and VT was evaluated by a mailed questionnaire. The information was verified by phone conversation and original patient records were acquired from the referring hospitals and primary care physicians. The time of the first AF episode, total number of symptomatic AF episodes, and a complete family history of documented AF episodes were obtained from all patients. The family history of AF was considered positive if at least one of the first-degree family members (i.e. parents, siblings, or children) had had ECG-documented AF episode(s). A clear family history of AF, suggesting autosomal dominant inheritance, was defined as documented AF in.30% of the first-degree family members. Genetic screening One family with 19 siblings had an extraordinary high occurrence of lone AF and saddleback-type ST-segment elevation (Figure 1). In this family, the SCN5A gene that has been previously described in the Brugada syndrome was screened from the affected proband of the family. 18 Genomic DNA was isolated from peripheral blood leucocytes using the commercial kit (Gentra System, Puregene, Minneapolis, MN, USA). Exons of the SCN5A were amplified and analysed by direct sequencing, using primers designed from the published gene sequence. Polymerase chain reaction products were purified with a commercial reagent (ExoSAP-IT, USB, Cleveland, OH, USA) and directly sequenced from both directions with an ABI PRISM 3100-Avant Automatic Sequencer (Foster City, CA, USA). Statistical analyses The data were analysed using SPSS 10.1 software (SPSS Inc., Chicago, IL, USA). The statistical significance of the differences between the populations was analysed with a two-sided Mann Whitney non-parametric test. A pre-specified value of P, 0.05 was considered statistically significant. Results Prevalence of saddleback-type ST-segment elevation ECGs The prevalence of saddleback-type ST-segment elevation (Figure 2A) was significantly higher among the patients with lone AF (17/168, 10%, 95% CI: 6 15%) than the healthy control subjects (2/541, 0.4%, 95% CI: 0 0.9%) (P, 0.001) (Figure 3). None of the patients with lone AF had coved-type ST-segment elevation (malignant type 1 Brugada ECG) at baseline ECG or after drug challenge with flecainide (n ¼ 8) or ajmaline (n ¼ 5) (Figure 2B). Clinical characteristics The clinical characteristics and echocardiographic data are presented in Table 1. With respect to the patients with lone AF, there were no differences in the duration of AF history (P ¼ 0.17), age at AF onset (P ¼ 0.10), total number of symptomatic AF episodes (P ¼ 0.73), fractional shortening (P ¼ 0.79), or LA size (P ¼ 0.77) between the subjects with saddleback ST-elevation and those with normal ECG. Family history of AF and genetic screening Many patients with lone AF and saddleback-type ST-segment elevation had familial clustering of lone AF. Overall, 59% of the patients with the saddleback ST-elevation and lone AF had at least one of their first-degree family members (i.e. parents, siblings, or children) with ECG-documented AF episode(s). In those patients with lone AF but no ECG abnormalities, the family history for lone AF was positive in 36% of the cases (P ¼ 0.07). A clear family history of AF (.30% of first-degree relatives with AF episodes) was significantly more common among the patients with the saddleback ST-elevation (24 vs. 7%, P ¼ 0.03). In one large family with 19 siblings, 11 had AF and six of them also exhibited the saddleback-type ST-segment elevation (Figure 1). The pedigree suggests an autosomal dominant pattern of inheritance. Genetic analysis of the proband in this particular family did not identify any mutations in the SCN5A gene. Therefore, all known or unknown mutations in this gene that may cause the Brugada syndrome have been excluded in this family. None of the patients with lone AF and the benign Brugada-type ECG had personal or family history of SCD, life-threatening ventricular arrhythmias, or syncope.

3 Familial clustering of lone AF in patients with ST-segment elevation 465 Figure 1 Pedigree of a family with a high prevalence of lone AF and saddleback-type ST-segment elevation. Females are represented by circles and males by squares. Subjects with AF are designated by filled symbols. In addition to the proband (marked with an arrow), five other siblings and the father of the siblings (who also had lone AF) had saddleback-type ST-segment elevation and these subjects are marked with a star (asterisk) under the symbol. Figure 2 Typical example of saddleback-type ST-segment elevation in a patient with lone AF in baseline ECG and during drug challenge. The precordial leads (V 1 V 6 ) of a subject who presented with a saddleback-type elevation of the J-point and the ST-segment at baseline ECG (A) and during drug challenge with flecainide (B) are also shown. Gain 10 mm/mv and paper speed 50 mm/s. See online supplementary material for a colour version of this figure. Discussion In the present study, the prevalence of saddleback-type ST-segment elevation (types 2 and 3) was significantly higher among patients with lone AF than in healthy control subjects. Many patients with saddleback-type ST-segment elevation abnormality exhibited familial clustering of lone AF. These findings suggest that (i) there may be a link between the electrophysiological mechanism(s) underlying saddleback-type ST-segment elevation and lone AF and (ii) genetic factors may be involved in the pathogenesis of AF in these patients. Saddleback-type ST-segment elevation and AF In agreement with our hypothesis, we found that the prevalence of saddleback-type ST-segment elevation was Figure 3 Prevalence of saddleback-type ST-segment elevation in patients with lone AF and healthy control subjects. The prevalence of saddleback-type ST-segment elevation among patients with lone AF is depicted with the column on the left (10%, 95% CI: 6 15%), whereas the column on the right represents the control population (0.4%, 95% CI: 0 0.9%). P, lone AF vs. control. significantly higher among the patients with lone AF than in the healthy control subjects. Although 20% of the patients with Brugada syndrome have AF, 7,8,16 to the best of our knowledge, there have been no prior studies examining the association between this specific ECG abnormality and AF in patients with no personal or family history of syncope, VT, or SCD. Despite the similar ECG repolarization abnormalities, several findings indicate that the patients described here do not have the classic Brugada syndrome. (i) According to a recently published consensus report, only type 1 ST-segment elevation (i.e. the coved type) is diagnostic for Brugada syndrome. 16 Here, all patients had either type 2 or type 3 (i.e. saddleback type) ECG, both at baseline and after drug challenge. (ii) In contrast to the patients with

4 466 M.J. Junttila et al. Table 1 Clinical characteristics of the control subjects and the patients with lone AF Control subjects (n ¼ 541) Patients with lone AF (n ¼ 168) Normal ECG (n ¼ 151) Saddleback-type ST-elevation (n ¼ 17) Age (years) Sex Male 274 (51%) 116 (77%) 14 (82%) Female 267 (49%) 35 (23%) 3 (18%) AF history No Yes Yes Age at AF onset (years) Duration of AF history (years) Number of symptomatic AF episodes AF in at least one 55 (36%) 10 (59%) family member AF in.30% of family members 11 (7%) 4 (24%) a Echocardiographic findings LA diameter (mm) Fractional shortening (%) a P, 0.05 vs. normal ECG. the Brugada syndrome, none of our patients with lone AF had a personal or family history of syncope, life-threatening VT, and SCD, although Brugada syndrome patients with atrial arrhythmias have been reported to have a higher risk of VT than those without atrial arrhythmias. 9 In our previous study, we found 18 patients with saddleback-type ST-segment elevation among over 3000 healthy subjects. 10 None of these subjects had a family history of syncope, VT, or SCD. Hence, despite the potential link between the electrophysiological features that cause the Brugada-type ECG pattern and lone AF, it is concluded that familiar AF described here is a disease entity distinct from the Brugada syndrome. Familial clustering of lone AF among subjects with saddleback-type ST-segment elevation The number of first-degree family members with AF was higher among the subjects with the saddleback-type ST-segment elevation. In particular, the subjects with the benign Brugada-type ECG pattern had a clear family history (i.e. AF in.30% of their first-degree relatives). There were no other differences in the clinical characteristics or arrhythmia history between the lone AF patients with and without saddleback ST-elevation. Thus, it is possible that a hereditary ion channel dysfunction may be involved in the pathogenesis of AF in these patients. The occurrence of lone AF in.30% of the first-degree relatives of the patients, i.e. familiar clustering of AF, is consistent with an autosomal dominant mode of inheritance with a high penetrance. Several population-based studies have recently described the familial aggregation of AF and a high risk of lone AF in individuals with parental AF. 1 For example, Ellinor et al. reported that 38% of the patients with lone AF had a family history of this disorder. A very high risk of lone AF has also been observed in affected siblings, with risk ratios of up to 70-fold among the male siblings of affected patients. 2 4 Brugada and coworkers described five Spanish families in whom persistent AF was inherited as an autosomal dominant trait with high penetrance. The arrhythmia was attributable to mutations in the region 10q22 24 of chromosome More recently, another locus for AF has been mapped to chromosome 6q14 16, 20 and a four-generation family with hereditary AF caused by a gain-of-function mutation in the KCNQ1 gene encoding a subunit of the cardiac potassium channel I Ks was described. 21 In contrast to the previous studies, 1 4,19 21 familiar clustering of AF, in our study, was associated with a distinct ECG abnormality. It is anticipated that the ongoing genetic analyses will clarify our understanding of the genetics of lone AF. Potential link between lone AF and saddleback-type ST-segment elevation Our data indicate that there may be a link between the electrophysiological features that cause the saddleback-type ST-segment elevation and lone AF. The familial clustering of lone AF is consistent with an autosomal dominant mode of inheritance with high penetrance. This and the close relationship between saddleback-type ST-segment elevation and lone AF support the concept that the disorder is caused by a mutation in some of the ion channels, which play a role both in the pathogenesis of AF and in the early ventricular repolarization. The ECG pattern in our patients mimicked that seen in patients with the Brugada syndrome and the SCN5A mutations, but had a more benign clinical characteristics. Mutations in the SCN5A gene were excluded in the genetic analysis. The other potential candidates include mutation(s) or a polymorphism in the genes that encode or regulate the function of the ion channels, which are active during the depolarization and early repolarization of the myocardial cells (e.g. I Na, I to, and I Kur ). Abnormal function of these channels could not only explain the ECG pattern but also has been shown to play an important role in the pathogenesis of AF by modulating atrial conduction velocity and refractoriness. 5 Conduction slowing would also have a major effect on generating AF. 5 Regional conduction slowing in the atrial muscle could also provide a similar

5 Familial clustering of lone AF in patients with ST-segment elevation 467 heterogenous substrate to AF. In the future, detailed evaluation of the P-wave morphology with signal average ECG or other novel methods as well as further genetic and electrophysiological studies may offer explanation for the link between the lone AF and the saddleback ST-elevation. In contrast, it is tempting to speculate that the ECG changes may not have been the cause of AF, but rather its consequence. It is well established that AF begets AF by inducing electrical and structural changes in the atria and ventricles. 22 At the cellular level, electrical remodelling is linked to downregulation of several ionic currents (e.g. I to, I Kur, I Ca,L, and I Na ). 23,24 At first, this seems to be incompatible with the ionic changes that initiate the saddleback-type ST-segment elevation. 25,26 One possible explanation for this paradoxical phenomenon is that the contribution of I to and I Kur to early myocardial repolarization becomes accentuated in remodelled tissues. In line with this idea, Blaauw et al. 27 recently showed that, unlike the effects of I Kr blockers, the effect of a specific I Kur /I to blocker was enhanced in the remodelled atria. Nevertheless, we found no correlation between the occurrence of saddleback-type ST-segment elevation and the duration of AF history or the total number of symptomatic AF episodes. Limitations Our data provide no direct evidence to identify the potential mutations underlying the ECG abnormality and lone AF. The genetic screening of the lone AF families and the benign Brugada-type ECG is ongoing. Therefore, we do not believe that one should speculate further on the genetic aetiology of this disorder. In comparison with many other countries, the genetic heritage in Finland is extremely homogeneous. 28 Therefore, it would be interesting to test whether our hypothesis is true also in other populations with different and less homogeneous genetic backgrounds. Finally, the potential effect of atrial remodelling on the ECG pattern of patients with lone AF needs to be evaluated in prospective trials. Conclusion Saddleback-type ST-segment elevation is significantly more frequent among patients with lone AF than healthy control subjects. The familial clustering of the disorder indicates that a hereditary ion channel dysfunction may be involved in the pathogenesis of ECG abnormalities and lone AF in these patients. Ongoing genetic screening of the families is expected to reveal more details of the molecular and genetic mechanisms of the disorder, which is characterized by lone AF and saddleback-type ST-segment elevation. Supplementary Material Supplementary material is available at European Heart Journal online. Acknowledgements We are grateful to Kai Lindgren, Antero Kesäniemi, and Heikki Kauma, who were a great help in this study by gathering the control data and part of the data of the study population. We would also like to thank Pirkko Huikuri, who helped us in the examination of the study subjects. We would like to thank the Medical Council of the Finnish Academy of Science, Helsinki, Finland, the Foundation for Cardiovascular Research, Helsinki, Finland, and the Aarne Koskelo Foundation, Helsinki, Finland for the support to our study. Conflict of interest: none declared. References 1. Fox CS, Parise H, D Agostino RB Sr, Lloyd-Jones DM, Vasan RS, Wang TJ, Levy D, Wolf PA, Benjamin EJ. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA 2004;291: Patton KK, Zacks ES, Chang JY, Shea MA, Ruskin JN, Macrae CA, Ellinor PT. Clinical subtypes of lone atrial fibrillation. Pacing Clin Electrophysiol 2005;28: Ellinor PT, Yoerger DM, Ruskin JN, MacRae CA. Familial aggregation in lone atrial fibrillation. Hum Genet 2005;118: Arnar DO, Thorvaldsson S, Manolio TA, Thorgeirsson G, Kristjansson K, Hakonarson H, Stefansson K. Familial aggregation of atrial fibrillation in Iceland. Eur Heart J 2006;27: Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002;415: Brugada P, Brugada J. Right bundle-branch block, persistent ST-segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome: a multicenter report. J Am Coll Cardiol 1992;20: Itoh H, Shimizu M, Ino H, Okeie K, Yamaguchi M, Fujino N, Mabuchi H, Hokuriku Brugada Study Group. Arrhythmias in patients with Brugadatype electrocardiographic findings. Jpn Circ J 2001;65: Eckardt L, Kirchhof P, Loh P, Schulze-Bahr E, Johna R, Wichter T, Breithardt G, Haverkamp W, Borggrefe M. Brugada syndrome and supraventricular tachyarrhythmias: a novel association? J Cardiovasc Electrophysiol 2001;6: Bordachar P, Reuter S, Garrigue S, Cai X, Hocini M, Jais P, Haissaguerre M, Clementy J. Incidence, clinical implications and prognosis of atrial arrhythmias in Brugada syndrome. Eur Heart J 2004;10: Junttila MJ, Raatikainen MJ, Karjalainen J, Kauma H, Kesaniemi YA, Huikuri HV. Prevalence and prognosis of subjects with Brugada-type ECG pattern in a young and middle-aged Finnish population. Eur Heart J 2004;10: Miyasaka Y, Tsuji H, Yamada K, Tokunaga S, Saito D, Imuro Y, Matsumoto N, Iwasaka T. Prevalence and mortality of the Brugada-type electrocardiogram in one city in Japan. J Am Coll Cardiol 2001;38: Matsuo K, Akahoshi M, Nakashima E, Suyama A, Seto S, Hayano M, Yano K. The prevalence, incidence and value of the Brugada-type electrocardiogram: a population based study of four decades. J Am Coll Cardiol 2001;38: Furuhashi M, Uno K, Tsuchihashi K, Nagahara D, Hyakukoku M, Ohtomo T, Satoh S, Nishimiya T, Shimamoto K. Prevalence of asymptomatic ST segment elevation in right precordial leads with right bundle branch block (Brugada-type ST shift) among the general Japanese population. Heart 2001;86: Atarashi H, Ogawa S, Harumi K, Sugimoto T, Inoue H, Murayama M, Toyama J, Hayakawa H, Idiopathic Ventricular Fibrillation Investigators. Three-year follow-up of patients with right bundle branch block and ST segment elevation in the right precordial leads: Japanese Registry of Brugada Syndrome. Idiopathic Ventricular Fibrillation Investigators. J Am Coll Cardiol 2001;37: Hermida JS, Lemoine JL, Aoun FB, Jarry G, Rey JL, Quiret JC. Prevalence of the Brugada syndrome in an apparently healthy population. Am J Cardiol 2000;86: Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, Gussak I, LeMarec H, Nademanee K, Perez Riera AR, Shimizu W, Schulze- Bahr E, Tan H, Wilde A. Brugada Syndrome Report of the Second Consensus Conference. Endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005;111: Huikuri HV, Pikkujamsa SM, Airaksinen KE, Ikaheimo MJ, Rantala AO, Kauma H, Lilja M, Kesaniemi YA. Sex-related differences in autonomic modulation of heart rate in middle-aged subjects. Circulation 1996;94: Chen Q, Kirsch GE, Zhang D, Brugada R, Brugada J, Brugada P, Potenza D, Moya A, Borggrefe M, Breithardt G, Ortiz-Lopez R, Wang Z, Antzelevitch C, O Brien RE, Schulze-Bahr E, Keating MT, Towbin JA, Wang Q. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998;392: Brugada R, Tapscott T, Czernuszewicz GZ, Marian AJ, Iglesias A, Mont L, Brugada J, Girona J, Domingo A, Bachinski LL, Roberts R. Identification

6 468 M.J. Junttila et al. of a genetic locus for familial atrial fibrillation. N Engl J Med 1997;336: Ellinor PT, Shin JT, Moore RK, Yoerger DM, MacRae CA. Locus for atrial fibrillation maps to chromosome 6q Circulation 2003;107: Chen YH, Xu SJ, Bendahhou S, Wang XL, Wang Y, Xu WY, Jin HW, Sun H, Su XY, Zhuang QN, Yang YQ, Li YB, Liu Y, Xu HJ, Li XF, Ma N, Mou CP, Chen Z, Barhanin J, Huang W. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 2003;299: Allessie MA. Atrial electrophysiologic remodeling: another vicious circle? J Cardiovasc Electrophysiol 1998;9: Van Wagoner DR, Pond AL, McCarthy PM, Trimmer JS, Nerbonne JM. Outward Kþ current densities Kv1.5 expression are reduced in chronic human atrial fibrillation. Circ Res 1997;80: Bosch RF, Nattel S. Cellular electrophysiology of atrial fibrillation. Cardiovasc Res 2002;54: Antzelevitch C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol 2001;12: Antzelevitch C, Brugada P, Brugada J, Brugada R. Brugada syndrome: from cell to bedside. Curr Probl Cardiol 2005;30: Blaauw Y, Gogelein H, Tieleman RG, van Hunnik A, Schotten U, Allessie MA. Early class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 2004;110: Peltonen M, Jalanko A, Varilo T. Molecular genetics of the Finnish disease heritage. Hum Mol Genet 1999;8:

Atrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology

Atrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology Atrial Fibrillation 2014 How to Treat How to Anticoagulate Allan Anderson, MD, FACC, FAHA Division of Cardiology Projection for Prevalence of Atrial Fibrillation: 5.6 Million by 2050 Projected number of

More information

European Heart Journal (2001) 22, 2290 2296 doi:10.1053/euhj.2001.2691, available online at http://www.idealibrary.com on

European Heart Journal (2001) 22, 2290 2296 doi:10.1053/euhj.2001.2691, available online at http://www.idealibrary.com on European Heart Journal (00), 90 96 doi:0.053/euhj.00.69, available online at http://www.idealibrary.com on New electrocardiographic leads and the procainamide test for the detection of the in sudden unexplained

More information

Diagnostic Scoring System for LQTS

Diagnostic Scoring System for LQTS Medical Coverage Policy Genetic Testing: Congenital Long QT Syndrome Device/Equipment Drug Medical Surgery Test Other Effective Date: 2/15/2011 Policy Last Updated: 2/21/2012 Prospective review is recommended/required.

More information

ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL)

ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL) ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL) By Prof. Dr. Helmy A. Bakr Mansoura Universirty 2014 AF Classification: Mechanisms of AF : Selected Risk Factors and Biomarkers for AF: WHY AF? 1. Atrial fibrillation

More information

How do you decide on rate versus rhythm control?

How do you decide on rate versus rhythm control? Heart Rhythm Congress 2014 How do you decide on rate versus rhythm control? Dr Ed Duncan Consultant Cardiologist & Electrophysiologist Define Rhythm Control DC Cardioversion Pharmacological AFFIRM study

More information

How to read the ECG in athletes: distinguishing normal form abnormal

How to read the ECG in athletes: distinguishing normal form abnormal How to read the ECG in athletes: distinguishing normal form abnormal Antonio Pelliccia, MD Institute of Sport Medicine and Science www.antoniopelliccia.it Cardiac adaptations to Rowing Vagotonia Sinus

More information

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra

RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent

More information

Management of Symptomatic Atrial Fibrillation

Management of Symptomatic Atrial Fibrillation Management of Symptomatic Atrial Fibrillation John F. MacGregor, MD, FHRS Associate Medical Director, Cardiac Electrophysiology PeaceHealth St. Joseph Medical Center, Bellingham, WA September 18, 2015

More information

January 14-15, 2011 SCA Conference 2

January 14-15, 2011 SCA Conference 2 Electrical Abnormalities: Long QT and Beyond Yaniv Bar-Cohen, M.D. Assistant Professor of Pediatrics Division of Cardiology / Electrophysiology Childrens Hospital Los Angeles Keck School of Medicine Genetic

More information

Genetic Long QT Syndrome GENETIC TESTING FOR LONG QT SYNDROME HS-148. Policy Number: HS-148. Original Effective Date: 1/21/2010

Genetic Long QT Syndrome GENETIC TESTING FOR LONG QT SYNDROME HS-148. Policy Number: HS-148. Original Effective Date: 1/21/2010 Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance

More information

The Emerging Atrial Fibrillation Epidemic: Treat It, Leave It or Burn It?

The Emerging Atrial Fibrillation Epidemic: Treat It, Leave It or Burn It? The Emerging Atrial Fibrillation Epidemic: Treat It, Leave It or Burn It? Indiana Chapter-ACC 17 th Annual Meeting Indianapolis, Indiana October 19, 2013 Deepak Bhakta MD FACC FACP FAHA FHRS CCDS Associate

More information

Atrial Fibrillation Cardiac rate control or rhythm control could be the key to AF therapy

Atrial Fibrillation Cardiac rate control or rhythm control could be the key to AF therapy Cardiac rate control or rhythm control could be the key to AF therapy Recent studies have proven that an option of pharmacologic and non-pharmacologic therapy is available to patients who suffer from AF.

More information

Presenter Disclosure Information

Presenter Disclosure Information 2:15 3 pm Managing Arrhythmias in Primary Care Presenter Disclosure Information The following relationships exist related to this presentation: Raul Mitrani, MD, FACC, FHRS: Speakers Bureau for Medtronic.

More information

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG

More information

Atrial Fibrillation and Cardiac Device Therapy RAKESH LATCHAMSETTY, MD DIVISION OF ELECTROPHYSIOLOGY UNIVERSITY OF MICHIGAN HOSPITAL ANN ARBOR, MI

Atrial Fibrillation and Cardiac Device Therapy RAKESH LATCHAMSETTY, MD DIVISION OF ELECTROPHYSIOLOGY UNIVERSITY OF MICHIGAN HOSPITAL ANN ARBOR, MI Atrial Fibrillation and Cardiac Device Therapy RAKESH LATCHAMSETTY, MD DIVISION OF ELECTROPHYSIOLOGY UNIVERSITY OF MICHIGAN HOSPITAL ANN ARBOR, MI Outline Atrial Fibrillation What is it? What are the associated

More information

How do you decide on rate versus rhythm control?

How do you decide on rate versus rhythm control? How do you decide on rate versus rhythm control? Dr. Mark O Neill Consultant Cardiologist & Electrophysiologist Assumptions Camm et al. EHJ 2010;Sept 25 epub Choice of strategy: Criteria for consideration

More information

Palpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust

Palpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust Palpitations & AF Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust Palpitations Frequent symptom Less than 50% associated with arrhythmia

More information

Guidelines for the diagnosis and management of Brugada Syndrome

Guidelines for the diagnosis and management of Brugada Syndrome The Cardiac Society of Australia and New Zealand Guidelines for the diagnosis and management of Brugada Syndrome Development of these guidelines was co-ordinated ordinated by A/Prof Jitendra Vohra and

More information

COVERAGE GUIDANCE: ABLATION FOR ATRIAL FIBRILLATION

COVERAGE GUIDANCE: ABLATION FOR ATRIAL FIBRILLATION COVERAGE GUIDANCE: ABLATION FOR ATRIAL FIBRILLATION Question: How should the EGBS Coverage Guidance regarding ablation for atrial fibrillation be applied to the Prioritized List? Question source: Evidence

More information

Recurrent AF: Choosing the Right Medication.

Recurrent AF: Choosing the Right Medication. In the name of God Shiraz E-Medical Journal Vol. 11, No. 3, July 2010 http://semj.sums.ac.ir/vol11/jul2010/89015.htm Recurrent AF: Choosing the Right Medication. Basamad Z. * Assistant Professor, Department

More information

Atrial Fibrillation: Drugs, Ablation, or Benign Neglect. Robert Kennedy, MD October 10, 2015

Atrial Fibrillation: Drugs, Ablation, or Benign Neglect. Robert Kennedy, MD October 10, 2015 Atrial Fibrillation: Drugs, Ablation, or Benign Neglect Robert Kennedy, MD October 10, 2015 Definitions 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary.

More information

Atrial Fibrillation An update on diagnosis and management

Atrial Fibrillation An update on diagnosis and management Dr Arvind Vasudeva Consultant Cardiologist Atrial Fibrillation An update on diagnosis and management Atrial fibrillation (AF) remains the commonest disturbance of cardiac rhythm seen in clinical practice.

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Genetic Testing for Cardiac Ion Channelopathies File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_cardiac_ion_channelopathies 10/2008 4/2015

More information

Innovation Platform: Sudden Cardiac Death

Innovation Platform: Sudden Cardiac Death Innovation Platform: Sudden Cardiac Death Prof. dr. Bart Loeys CRC Antwerp General Assembly VzW Board of Directors Strategic Advisory Board Staff: 1 executive director 1 ICT manager 1 financial administration

More information

Danish Cardiovascular Research Academy and Faculty of Health Sciences University of Copenhagen

Danish Cardiovascular Research Academy and Faculty of Health Sciences University of Copenhagen Danish Cardiovascular Research Academy and Faculty of Health Sciences University of Copenhagen PhD course: Cardiac arrhythmias - Aim and content: Cardiac arrhythmia represents a wide spectrum of abnormalities

More information

Life Threatening EKG s In The Office. Joseph A Manfredi, MD, FACC, FHRS GHS Cardiovascular Symposium

Life Threatening EKG s In The Office. Joseph A Manfredi, MD, FACC, FHRS GHS Cardiovascular Symposium Life Threatening EKG s In The Office Joseph A Manfredi, MD, FACC, FHRS GHS Cardiovascular Symposium January 24 th, 2015 Disclosures Speaker Honorariums: STJM, Boston Scientific Advisory role: Medtronic

More information

Natural History of Early Repolarization in the Inferior Leads

Natural History of Early Repolarization in the Inferior Leads ORIGINAL ARTICLE Natural History of Early Repolarization in the Inferior Leads Ricardo Stein, M.D., Karim Sallam, M.D., Chandana Adhikarla, M.D., Madhavi Boga, M.D., Alexander D. Wood, B.Sc., and Victor

More information

How to control atrial fibrillation in 2013 The ideal patient for a rate control strategy

How to control atrial fibrillation in 2013 The ideal patient for a rate control strategy How to control atrial fibrillation in 2013 The ideal patient for a rate control strategy L. Pison, MD Advances in Cardiac Arrhythmias and Great Innovations in Cardiology - Torino, September 28 th 2013

More information

How should we treat atrial fibrillation in heart failure

How should we treat atrial fibrillation in heart failure Advances in Cardiac Arrhhythmias and Great Innovations in Cardiology Torino, 23/24 Ottobre 2015 How should we treat atrial fibrillation in heart failure Matteo Anselmino Dipartimento Scienze Mediche Città

More information

Københavns Universitet

Københavns Universitet university of copenhagen Københavns Universitet Automatic J-point Location in Subjects with Electrocardiographic Early Repolarization Melgaard, Jacob; Struijk, Johannes J.; Hansen, John; Kanters, Jørgen

More information

ATRIAL FIBRILLATION: Scope of the Problem. October 2015

ATRIAL FIBRILLATION: Scope of the Problem. October 2015 ATRIAL FIBRILLATION: Scope of the Problem October 2015 Purpose of the Presentation Review the worldwide incidence and prognosis associated with atrial fibrillation (AF) Identify the types of AF, clinical

More information

Tachyarrhythmias (fast heart rhythms)

Tachyarrhythmias (fast heart rhythms) Patient information factsheet Tachyarrhythmias (fast heart rhythms) The normal electrical system of the heart The heart has its own electrical conduction system. The conduction system sends signals throughout

More information

2014: nowadays the one shot technologies and the injectable monitor allow a wide and complete AF patient management. Why shouldn t we use them?

2014: nowadays the one shot technologies and the injectable monitor allow a wide and complete AF patient management. Why shouldn t we use them? 2014: nowadays the one shot technologies and the injectable monitor allow a wide and complete AF patient management. Why shouldn t we use them? Gaetano Senatore DIVISION OF CARDIOLOGY HOSPITAL OF CIRIE

More information

Long QT. Long QT Syndrome. A Guide for

Long QT. Long QT Syndrome. A Guide for Long QT Long QT Syndrome A Guide for Introduction Long QT syndrome (LQTS) is a genetic heart disorder due to the malfunction of cardiac ion channels that results in 4,000 deaths annually in the United

More information

Atrial Fibrillation The Basics

Atrial Fibrillation The Basics Atrial Fibrillation The Basics Family Practice Symposium Tim McAveney, M.D. 10/23/09 Objectives Review the fundamentals of managing afib Discuss the risks for stroke and the indications for anticoagulation

More information

Electrocardiographic Issues in Williams Syndrome

Electrocardiographic Issues in Williams Syndrome Electrocardiographic Issues in Williams Syndrome R. Thomas Collins II, MD Assistant Professor, Pediatrics and Internal Medicine University of Arkansas for Medical Sciences Arkansas Children s Hospital

More information

Acquired, Drug-Induced Long QT Syndrome

Acquired, Drug-Induced Long QT Syndrome Acquired, Drug-Induced Long QT Syndrome A Guide for Patients and Health Care Providers Sudden Arrhythmia Death Syndromes (SADS) Foundation 508 E. South Temple, Suite 202 Salt Lake City, Utah 84102 800-STOP

More information

Introduction to Electrocardiography. The Genesis and Conduction of Cardiac Rhythm

Introduction to Electrocardiography. The Genesis and Conduction of Cardiac Rhythm Introduction to Electrocardiography Munther K. Homoud, M.D. Tufts-New England Medical Center Spring 2008 The Genesis and Conduction of Cardiac Rhythm Automaticity is the cardiac cell s ability to spontaneously

More information

ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY

ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY Care Pathway Triage category ATRIAL FIBRILLATION PATHWAY ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY AF/ FLUTTER IS PRIMARY REASON FOR PRESENTATION YES NO ONSET SYMPTOMS OF AF./../ TIME DURATION OF AF

More information

Management of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39

Management of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39 Management of ATRIAL FIBRILLATION in general practice 22 BPJ Issue 39 What is atrial fibrillation? Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in primary care. It is often

More information

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains

More information

Natural History of the Electrocardiographic Pattern of Early Repolarization in Ambulatory Patients

Natural History of the Electrocardiographic Pattern of Early Repolarization in Ambulatory Patients Natural History of the Electrocardiographic Pattern of Early Repolarization in Ambulatory Patients Chandana Adhikarla, MD b, *, Madhavi Boga, MD b, Alexander D. Wood b,c, and Victor F. Froelicher, MD a,b

More information

Atrial Fibrillation (AF) March, 2013

Atrial Fibrillation (AF) March, 2013 Atrial Fibrillation (AF) March, 2013 This handout is meant to help with discussions about the condition, and it is not a complete discussion of AF. We hope it will complement your appointment with one

More information

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic

More information

Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity

Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity Jean-Luc MONIN, MD, PhD Henri Mondor University Hospital Créteil, FRANCE Disclosures : None 77-year-old woman, mild dyspnea

More information

Managing the Patient with Atrial Fibrillation

Managing the Patient with Atrial Fibrillation Pocket Guide Managing the Patient with Atrial Fibrillation Updated April 2012 Editor Stephen R. Shorofsky, MD, Ph.D. Assistant Editors Anastasios Saliaris, MD Shawn Robinson, MD www.hrsonline.org DEFINITION

More information

Diagnosis Code Crosswalk : ICD-9-CM to ICD-10-CM Cardiac Rhythm and Heart Failure Diagnoses

Diagnosis Code Crosswalk : ICD-9-CM to ICD-10-CM Cardiac Rhythm and Heart Failure Diagnoses Diagnosis Code Crosswalk : to 402.01 Hypertensive heart disease, malignant, with heart failure 402.11 Hypertensive heart disease, benign, with heart failure 402.91 Hypertensive heart disease, unspecified,

More information

12-Lead EKG Interpretation. Judith M. Haluka BS, RCIS, EMT-P

12-Lead EKG Interpretation. Judith M. Haluka BS, RCIS, EMT-P 12-Lead EKG Interpretation Judith M. Haluka BS, RCIS, EMT-P ECG Grid Left to Right = Time/duration Vertical measure of voltage (amplitude) Expressed in mm P-Wave Depolarization of atrial muscle Low voltage

More information

Addendum to the Guideline on antiarrhythmics on atrial fibrillation and atrial flutter

Addendum to the Guideline on antiarrhythmics on atrial fibrillation and atrial flutter 22 July 2010 EMA/CHMP/EWP/213056/2010 Addendum to the Guideline on antiarrhythmics on atrial fibrillation and atrial flutter Draft Agreed by Efficacy Working Party July 2008 Adoption by CHMP for release

More information

BIPOLAR LIMB LEADS UNIPOLAR LIMB LEADS PRECORDIAL (UNIPOLAR) LEADS VIEW OF EACH LEAD INDICATIVE ECG CHANGES

BIPOLAR LIMB LEADS UNIPOLAR LIMB LEADS PRECORDIAL (UNIPOLAR) LEADS VIEW OF EACH LEAD INDICATIVE ECG CHANGES BIPOLAR LIMB LEADS Have both a distinctive positive and negative pole. Lead I LA (positive) RA (negative) Lead II LL (positive) RA (negative) Lead III LL (positive) LA (negative) UNIPOLAR LIMB LEADS Have

More information

INHERIT. The Lancet Diabetes & Endocrinology In press

INHERIT. The Lancet Diabetes & Endocrinology In press INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy a Randomized Intervention Trial with losartan Anna Axelsson, Kasper Iversen, Niels Vejlstrup, Carolyn

More information

GERIATRYCZNE PROBLEMY KLINICZNE/GERIATRICS MEDICAL PROBLEMS

GERIATRYCZNE PROBLEMY KLINICZNE/GERIATRICS MEDICAL PROBLEMS 65 G E R I A T R I A 2011; 5: 65-69 GERIATRYCZNE PROBLEMY KLINICZNE/GERIATRICS MEDICAL PROBLEMS Otrzymano/Submitted: 24.02.2011 Poprawiono/Corrected: 01.03.2011 Zaakceptowano/Accepted: 06.03.2011 Akademia

More information

LAST NAME VAT NUMBER. PHONE (Important for possible case discussion)

LAST NAME VAT NUMBER. PHONE (Important for possible case discussion) Long QT Panel CUSTOMER INFORMATION FIRST NAME LAST NAME ORGANIZATION VAT NUMBER BILLING ADDRESS 1ST LINE BILLING ADDRESS 2ND LINE POST CODE CITY COUNTRY EMAIL (Required) PHONE (Important for possible case

More information

INTRODUCTORY GUIDE TO IDENTIFYING ECG IRREGULARITIES

INTRODUCTORY GUIDE TO IDENTIFYING ECG IRREGULARITIES INTRODUCTORY GUIDE TO IDENTIFYING ECG IRREGULARITIES NOTICE: This is an introductory guide for a user to understand basic ECG tracings and parameters. The guide will allow user to identify some of the

More information

1p36 and the Heart. John Lynn Jefferies, MD, MPH, FACC, FAHA

1p36 and the Heart. John Lynn Jefferies, MD, MPH, FACC, FAHA 1p36 and the Heart John Lynn Jefferies, MD, MPH, FACC, FAHA Director, Advanced Heart Failure and Cardiomyopathy Services Associate Professor, Pediatric Cardiology and Adult Cardiovascular Diseases Associate

More information

Tips and Tricks to Demystify 12 Lead ECG Interpretation

Tips and Tricks to Demystify 12 Lead ECG Interpretation Tips and Tricks to Demystify 12 Lead ECG Interpretation Mission: Lifeline North Dakota Regional EMS and Hospital Conference Samantha Kapphahn, DO Essentia Health- Interventional Cardiology June 5th, 2014

More information

New in Atrial Fibrillation

New in Atrial Fibrillation New in Atrial Fibrillation September 2011 Stroke prevention more options Rhythm Control -drugs - alternatives to drugs; ablation Rate Control - pace + ablate A-FIB Dell Stroke Risk AFib Two Principles

More information

UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD. Ex parte VINOD SHARMA and DANIEL C. SIGG

UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD. Ex parte VINOD SHARMA and DANIEL C. SIGG UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD Ex parte VINOD SHARMA and DANIEL C. SIGG Appeal 2012-000284 Technology Center 1600 Before ERIC GRIMES, FRANCISCO C. PRATS,

More information

PRACTICAL APPROACH TO SVT. Graham C. Wong MD MPH Division of Cardiology Vancouver General Hospital University of British Columbia

PRACTICAL APPROACH TO SVT. Graham C. Wong MD MPH Division of Cardiology Vancouver General Hospital University of British Columbia PRACTICAL APPROACH TO SVT Graham C. Wong MD MPH Division of Cardiology Vancouver General Hospital University of British Columbia CONDUCTION SYSTEM OF THE HEART SA node His bundle Left bundle AV node Right

More information

Automatic External Defibrillators

Automatic External Defibrillators Last Review Date: May 27, 2016 Number: MG.MM.DM.10dC2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth

More information

BASIC STANDARDS FOR RESIDENCY TRAINING IN CARDIOLOGY

BASIC STANDARDS FOR RESIDENCY TRAINING IN CARDIOLOGY BASIC STANDARDS FOR RESIDENCY TRAINING IN CARDIOLOGY American Osteopathic Association and the American College of Osteopathic Internists Specific Requirements For Osteopathic Subspecialty Training In Cardiology

More information

Atrial Fibrillation Peter Santucci, MD Revised May, 2008

Atrial Fibrillation Peter Santucci, MD Revised May, 2008 Atrial Fibrillation Peter Santucci, MD Revised May, 2008 Atrial fibrillation (AF) is an irregular, disorganized rhythm characterized by a lack of organized mechanical atrial activity. The atrial rate is

More information

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with

More information

Electrocardiography Review and the Normal EKG Response to Exercise

Electrocardiography Review and the Normal EKG Response to Exercise Electrocardiography Review and the Normal EKG Response to Exercise Cardiac Anatomy Electrical Pathways in the Heart Which valves are the a-v valves? Closure of the a-v valves is associated with which heart

More information

Atrial Fibrillation: Do We Have A Cure? Raymond Kawasaki, MD AMG Electrophysiology February 21, 2015

Atrial Fibrillation: Do We Have A Cure? Raymond Kawasaki, MD AMG Electrophysiology February 21, 2015 Atrial Fibrillation: Do We Have A Cure? Raymond Kawasaki, MD AMG Electrophysiology February 21, 2015 Disclaimer I have no relationships to disclose Do we have a cure for Atrial Fibrillation? The short

More information

Atrial Fibrillation Catheter Ablation versus Surgical Ablation Treatment: FAST A Two-Center Randomized Clinical Trial

Atrial Fibrillation Catheter Ablation versus Surgical Ablation Treatment: FAST A Two-Center Randomized Clinical Trial Atrial Fibrillation Catheter Ablation versus Surgical Ablation Treatment: FAST A Two-Center Randomized Clinical Trial Lucas Boersma, WimJan van Boven, Alaaddin Yilmaz, Johannes Kelder, Maurits Wijffels

More information

510(k) Summary May 7, 2012

510(k) Summary May 7, 2012 510(k) Summary Medicalgorithmics 510(k) Premarket Notification 510(k) Summary May 7, 2012 1. Submitter Name and Address Medicalgorithmics LLC 245 West 107th St., Suite 11A New York, NY 10025, USA Contact

More information

Cardiopatie Aritmogene nel Giovane

Cardiopatie Aritmogene nel Giovane Firenze, 16 Novembre 2012 Cardiopatie Aritmogene nel Giovane Prof. Luigi Padeletti Università degli Studi di Firenze 1) Long QT Syndrome 2) Short QT Syndrome 3) J wave Syndrome: Early Repolarization Syndrome

More information

Equine Cardiovascular Disease

Equine Cardiovascular Disease Equine Cardiovascular Disease 3 rd most common cause of poor performance in athletic horses (after musculoskeletal and respiratory) Cardiac abnormalities are rare Clinical Signs: Poor performance/exercise

More information

NEONATAL & PEDIATRIC ECG BASICS RHYTHM INTERPRETATION

NEONATAL & PEDIATRIC ECG BASICS RHYTHM INTERPRETATION NEONATAL & PEDIATRIC ECG BASICS & RHYTHM INTERPRETATION VIKAS KOHLI MD FAAP FACC SENIOR CONSULATANT PEDIATRIC CARDIOLOGY APOLLO HOSPITAL MOB: 9891362233 ECG FAX LINE: 011-26941746 THE BASICS: GRAPH PAPER

More information

Section Four: Pulmonary Artery Waveform Interpretation

Section Four: Pulmonary Artery Waveform Interpretation Section Four: Pulmonary Artery Waveform Interpretation All hemodynamic pressures and waveforms are generated by pressure changes in the heart caused by myocardial contraction (systole) and relaxation/filling

More information

TOP 5. The term cardiac arrhythmia encompasses all cardiac. Arrhythmias in Dogs & Cats. Sinus Arrhythmia. TOP 5 Arrhythmias Seen in Dogs & Cats

TOP 5. The term cardiac arrhythmia encompasses all cardiac. Arrhythmias in Dogs & Cats. Sinus Arrhythmia. TOP 5 Arrhythmias Seen in Dogs & Cats Top 5 ardiology Peer reviewed TOP 5 rrhythmias in Dogs & ats shley Jones, DVM mara Estrada, DVM, DVIM (ardiology) University of Florida The term cardiac arrhythmia encompasses all cardiac rhythms other

More information

Title: Genetics and Hearing Loss: Clinical and Molecular Characteristics

Title: Genetics and Hearing Loss: Clinical and Molecular Characteristics Session # : 46 Day/Time: Friday, May 1, 2015, 1:00 4:00 pm Title: Genetics and Hearing Loss: Clinical and Molecular Characteristics Presenter: Kathleen S. Arnos, PhD, Gallaudet University This presentation

More information

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES. Hossam Bahy, MD (1992 2012), 19 tools have been identified 11 stroke scores 1

More information

National Medicines Information Centre

National Medicines Information Centre National Medicines Information Centre ST. JAMES S HOSPITAL DUBLIN 8 TEL 01-4730589 or 1850-727-727 FAX 01-4730596 www.nmic.ie THE CONTEMPORARY MANAGEMENT OF ATRIAL FIBRILLATION VOLUME 12 NUMBER 3 2006

More information

Rome, Italy December 4-7, 2012 Rome Cavalieri TIMETABLE

Rome, Italy December 4-7, 2012 Rome Cavalieri TIMETABLE Rome, Italy December 4-7, 2012 Rome Cavalieri Monday, December 3 ROOM Terrazza Monte Mario PATIENT MANAGEMENT CONCEPTS AND CONTROVERSIES IN ELECTROPHYSIOLOGY BIOTRONIK International Fellows Program (IFP)

More information

Management of Pacing Wires After Cardiac Surgery

Management of Pacing Wires After Cardiac Surgery Management of Pacing Wires After Cardiac Surgery David E. Lizotte, Jr. PA C, MPAS, FAPACVS President, Association of Physician Assistants in Cardiovascular Surgery Conflicts: None Indications 2008 Journal

More information

Current Management of Atrial Fibrillation DISCLOSURES. Heart Beat Anatomy. I have no financial conflicts to disclose

Current Management of Atrial Fibrillation DISCLOSURES. Heart Beat Anatomy. I have no financial conflicts to disclose Current Management of Atrial Fibrillation Mary Macklin, MSN, APRN Concord Hospital Cardiac Associates DISCLOSURES I have no financial conflicts to disclose Book Women: Fit at Fifty. A Guide to Living Long.

More information

Medical Policy Manual. Topic: Genetic Testing for Cardiac Ion Channelopathies Date of Origin: December 2012

Medical Policy Manual. Topic: Genetic Testing for Cardiac Ion Channelopathies Date of Origin: December 2012 Medical Policy Manual Topic: Genetic Testing for Cardiac Ion Channelopathies Date of Origin: December 2012 Section: Genetic Testing Last Reviewed Date: December 2015 Policy No: 07 Effective Date: January

More information

The P Wave: Indicator of Atrial Enlargement

The P Wave: Indicator of Atrial Enlargement Marquette University e-publications@marquette Physician Assistant Studies Faculty Research and Publications Health Sciences, College of 8-12-2010 The P Wave: Indicator of Atrial Enlargement Patrick Loftis

More information

ATRIAL FIBRILLATION RATE VS RHYTHM CONTROL NCVH BIRMINGHAM 2014

ATRIAL FIBRILLATION RATE VS RHYTHM CONTROL NCVH BIRMINGHAM 2014 ATRIAL FIBRILLATION RATE VS RHYTHM CONTROL NCVH BIRMINGHAM 2014 Facts 4 million or so people have atrial fibrillation 16 billion dollars spent yearly in USA 30% of strokes attributable to AF and AFL 3-5

More information

DISCLOSURE. Atrial Fibrillation Management An Evidence-based Approach OBJECTIVES BACKGROUND AFFIRM 9/16/2015

DISCLOSURE. Atrial Fibrillation Management An Evidence-based Approach OBJECTIVES BACKGROUND AFFIRM 9/16/2015 Death (%) Mortality (%) 9/16/2015 DISCLOSURE Atrial Fibrillation Management An Evidence-based Approach Jonathon Adams, MD, FHRS Relevant Financial Relationship(s) None Off Label Usage None OBJECTIVES What

More information

TABLE 1 Clinical Classification of AF. New onset AF (first detected) Paroxysmal (<7 days, mostly < 24 hours)

TABLE 1 Clinical Classification of AF. New onset AF (first detected) Paroxysmal (<7 days, mostly < 24 hours) Clinical Practice Guidelines for the Management of Patients With Atrial Fibrillation Deborah Ritchie RN, MN, Robert S Sheldon MD, PhD Cardiovascular Research Group, University of Calgary, Alberta Partly

More information

Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease

Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease Heart Failure Center Hadassah University Hospital Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease Israel Gotsman MD The Heart Failure Center, Heart Institute Hadassah University

More information

Atrial Fibrillation: A Different Perspective. Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital

Atrial Fibrillation: A Different Perspective. Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital Atrial Fibrillation: A Different Perspective Michael Heffernan MD PhD FRCPC FACC Staff Cardiologist Oakville Hospital Faculty/Presenter Disclosure Faculty: Dr. Michael Heffernan Relationships with commercial

More information

A Case of Long QT Syndrome Type 3 Aggravated by Beta-Blockers and Alleviated by Mexiletine: The Role of Epinephrine Provocation Test

A Case of Long QT Syndrome Type 3 Aggravated by Beta-Blockers and Alleviated by Mexiletine: The Role of Epinephrine Provocation Test Case Report http://dx.doi.org/10.3349/ymj.2013.54.2.529 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 54(2):529-533, 2013 A Case of Long QT Syndrome Type 3 Aggravated by Beta-Blockers and Alleviated

More information

The QT interval: Too long, too short or just right

The QT interval: Too long, too short or just right CONTEMPORARY REVIEW The QT interval: Too long, too short or just right Sami Viskin, MD From Tel-Aviv Sourasky Medical Center, Sackler-School of Medicine, Tel Aviv, Israel. The hallmark of the congenital

More information

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013

Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Kevin Saunders MD CCFP Rivergrove Medical Clinic Wellness Institute @ SOGH April 17 2013 Family physician with Rivergrove Medical Clinic Practice in the north end since 1985 Medical Director of the Wellness

More information

Usefulness of Epinephrine Test in the Congenital Long QT Syndrome

Usefulness of Epinephrine Test in the Congenital Long QT Syndrome Usefulness of Epinephrine Test in the Congenital Long QT Syndrome Wataru Shimizu M.D., Ph.D. CASE PRESENTATION A 14-year old Japanese boy was successfully resuscitated from cardiac arrest (near drowning)

More information

Sporadic or short episodes of paroxysmal atrial fibrillation - still a need for antithrombotic therapy?

Sporadic or short episodes of paroxysmal atrial fibrillation - still a need for antithrombotic therapy? Sporadic or short episodes of paroxysmal atrial fibrillation - still a need for antithrombotic therapy? Carina Blomström Lundqvist Dept Cardiology, Uppsala University, Sweden Patterns of AF Terminates

More information

New Approaches to Anticoagulation in Atrial Fibrillation

New Approaches to Anticoagulation in Atrial Fibrillation New Approaches to Anticoagulation in Atrial Fibrillation Hugh Calkins M.D. Nicholas J. Fortuin Professor of Cardiology Professor of Medicine Director of Electrophysiology Johns Hopkins Medical Institutions

More information

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations.

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. INTRODUCTION Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. Although decrease in cardiovascular mortality still major cause of morbidity & burden of disease.

More information

Atrial Fibrillation in the ICU: Attempting to defend 4 controversial statements

Atrial Fibrillation in the ICU: Attempting to defend 4 controversial statements Atrial Fibrillation in the ICU: Attempting to defend 4 controversial statements Salmaan Kanji, Pharm.D. The Ottawa Hospital The Ottawa Hospital Research Institute Conflict of Interest No financial, proprietary

More information

ESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease

ESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease Diabetes, prediabetes and cardiovascular disease Classes of recommendations Levels of evidence Recommended treatment targets for patients with diabetes and CAD Definition, classification and screening

More information

Signal-averaged electrocardiography late potentials

Signal-averaged electrocardiography late potentials SIGNAL AVERAGED ECG INTRODUCTION Signal-averaged electrocardiography (SAECG) is a special electrocardiographic technique, in which multiple electric signals from the heart are averaged to remove interference

More information

Introduction to Electrophysiology. Wm. W. Barrington, MD, FACC University of Pittsburgh Medical Center

Introduction to Electrophysiology. Wm. W. Barrington, MD, FACC University of Pittsburgh Medical Center Introduction to Electrophysiology Wm. W. Barrington, MD, FACC University of Pittsburgh Medical Center Objectives Indications for EP Study How do we do the study Normal recordings Abnormal Recordings Limitations

More information

Atrial Fibrillation (AF) Explained

Atrial Fibrillation (AF) Explained James Paget University Hospitals NHS Foundation Trust Atrial Fibrillation (AF) Explained Patient Information Contents What are the symptoms of atrial fibrillation (AF)? 3 Normal heartbeat 4 How common

More information

Cardioversion for. Atrial Fibrillation. Your Heart s Electrical System Cardioversion Living with Atrial Fibrillation

Cardioversion for. Atrial Fibrillation. Your Heart s Electrical System Cardioversion Living with Atrial Fibrillation Cardioversion for Atrial Fibrillation Your Heart s Electrical System Cardioversion Living with Atrial Fibrillation When You Have Atrial Fibrillation You ve been told you have a heart condition called atrial

More information

CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. Las Vegas, Nevada Bellagio March 4 6, 2016. Participating Faculty

CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE. Las Vegas, Nevada Bellagio March 4 6, 2016. Participating Faculty CARDIO/PULMONARY MEDICINE FOR PRIMARY CARE Las Vegas, Nevada Bellagio March 4 6, 2016 Participating Faculty Friday, March 4th: 7:30 am - 8:00 am Registration and Hot Breakfast 8:00 am - 9:00 am Pulmonary

More information

Anatomi & Fysiologi 060301. The cardiovascular system (chapter 20) The circulation system transports; What the heart can do;

Anatomi & Fysiologi 060301. The cardiovascular system (chapter 20) The circulation system transports; What the heart can do; The cardiovascular system consists of; The cardiovascular system (chapter 20) Principles of Anatomy & Physiology 2009 Blood 2 separate pumps (heart) Many blood vessels with varying diameter and elasticity

More information